default author photo

Sean Collins

Gilead Sciences, Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

146

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Ritonavir-Boosted Protease Inhibitor-Based Antiretroviral Therapy in Persons with HIV and Viral Suppression on Second-Line Therapy: An Open-Label Randomized Non-Inferiority Trial

Number of pages: 27 Posted: 02 Jan 2025
Damocles Patrice Severe, Samuel Pierre, Fabienne Homeus, Jean Bernard Marc, Letizia Trevisi, Maria Linda Aristhomen, Guirlaine R. Bernadin, Kerlyne Lavoile, Vanessa Rivera, Carl Frederic Duchatellier, Marie Josee Joseph, Johnny Wu, Vanessa Rouzier, Fabiola Preval, Evens Jean, Jodany Bernadin, Abigail Zion, Guyrlaine Pierre-Louis Forestal, Santiago Ávila-Ríos, Claudia Garcia Morales, Adina Zhang, Dennis Israelski, Alexandra Apollon, Emelyne Dumont, Elizabeth Fox, Pierre Cremieux, Jean William Pape, Sean Collins, Bernard Liautaud, Paul E. Sax and Serena Koenig
Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Department of Global Health and Social Medicine, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), National Institute of Respiratory Diseases ”Ismael Cosío Villegas” - Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Analysis Group, Inc., Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Cornell University, Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Division of Infectious Disease and Harvard University - Harvard Medical School
Downloads 146 (505,974)

Abstract:

Loading...

HIV, INSTI, bictegravir, protease inhibitor, tenofovir alafenamide, tenofovir disoproxil fumarate